Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
70 participants
INTERVENTIONAL
2008-06-30
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sildenafil in Sever Intrauterine Growth Retardation
NCT03153215
Sildenafil Citrate for Treatment of Growth-restricted Fetuses
NCT03177824
Sildenafil Versus Low Molecular Weight Heparin in Fetal Growth Restriction Treatment
NCT03230162
A Trial Evaluating the Role of Sildenafil in the Treatment of Fetal Growth Restriction
NCT02590536
Effect of Sildenafil Citrate on Uteri- Placental Perfusion, Doppler Indices in Growth Restricted Fetuses
NCT02362399
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Doppler waveform analysis of these pregnancies suggests compromised uteroplacental circulation and placental hypoperfusion.
Our aim is to assess if sildenafil citrate could improve vasodilatation in FGR pregnancies.
Sildenafil citrate may offer a potential therapeutic strategy to improve uteroplacental perfusion in FGR.
Animal studies suggest that phosphodiesterase-5 (PDE5) inhibitors, such as sildenafil citrate, may improve uterine blood flow .
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
sildenafil
sildenafil
50 mg TDS orally until birth
Placebo control
placebo
50mg tid
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sildenafil
50 mg TDS orally until birth
placebo
50mg tid
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* history of cardiovascular morbidity specially of right heart side
* drug or alcohol abusers
* systolic BP more than 210 mm Hg or diastolic BP more than 120 mm Hg
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tehran University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tehran University of Medical Sciences
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
marzieh vahid dastjerdi, M.D.
Role: STUDY_CHAIR
Iranian's ministery of health
Sayedeh Afagh Hosseini, MD.
Role: STUDY_DIRECTOR
resident of OB&GYN
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tehran UMS
Tehran, Tehran Province, Iran
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
87-821
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.